L002 (NSC764414) - p300 Inhibitor. CAS# 321695-57-2 Catalog No.:M60198-10S InChi: InChI=1S/C19H17Cl3N4O3/c1-28-8-9-29-19-24-18(12-2-7-15(21)16(22)10-12)26(25-19)14-5-3-13(4-6-14)23-17(27)11-20/h2-7

InChi: InChI=1S/C19H17Cl3N4O3/c1-28-8-9-29-19-24-18(12-2-7-15(21)16(22)10-12)26(25-19)14-5-3-13(4-6-14)23-17(27)11-20/h2-7

(2006) Proc Amer Assoc Cancer Res

is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications

and ~1 µM for JMJD3 (KDM6B) and JMJD2C (KDM4C)

InChiKey: ULBOWKXOFOTCMU-NLDKGBHCSA-N

L002 (NSC764414) - p300 Inhibitor. CAS# 321695-57-2 Catalog No.:M60198-10S InChi: InChI=1S/C19H17Cl3N4O3/c1-28-8-9-29-19-24-18(12-2-7-15(21)16(22)10-12)26(25-19)14-5-3-13(4-6-14)23-17(27)11-20/h2-7L002 (NSC764414), CAS No. 321695 57 2, is a novel selective, cell permeable and reversible inhibitor of p300 histone acetyl transferase (IC50 ~1. 98 M). It has no activity in histone methyltransferases tested, including DOT1, EZH1, G9a, PRMT1, SETD2, SET7 9, SMYD2, and SUV39H2 etc. L002 was shown to occupy Ac CoA binding pocket of p300, and is less potent to CBP, PCAF, GCN5 and GNAT. It suppresses Histone H3 and H4 acetylation in triple negative